Innovator Liability: A Pandora's Box For Pharma Cos.?
By Monee Hanna and Nicholas Janizeh ( April 2, 2018, 1:30 PM EDT) -- "[O]ur careful review of the federal regulatory scheme ... persuades us that a brand-name drug manufacturer has the duty ... to warn of the risks about which it knew or reasonably should have known, regardless of whether the consumer is prescribed the brand-name drug or its [competitors'] generic 'bioequivalent[s].'" —The California Supreme Court in T.H. v. Novartis...
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.